NASDAQ · PPCB
Propanc Biopharma, Inc.
$1.93-$0.19 (-8.77%)
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
Loading market information…
OTC · NVTAQ · USD
Stock price, earnings
Quote as of Aug 7, 2024, 06:12 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Invitae Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Invitae Corporation (NVTAQ) operates as a medical genetics enterprise, striving to advance healthcare outcomes by furnishing crucial genetic information to individuals across the United States, Canada, and other international markets. The company's diverse offerings include genetic diagnostic services for various clinical domains, such as hereditary cancer risk assessment, targeted oncology, women's health concerns, rare medical conditions, and pharmacogenomics (the study of how genes affect a person's response to drugs). Additionally, Invitae delivers innovative digital health solutions and comprehensive health data management services. Its broad client base encompasses patients, healthcare practitioners, biopharmaceutical firms, and other strategic alliances. Established in 2010, the company originally operated as Locus Development, Inc. before adopting the Invitae Corporation name in 2012. Its corporate headquarters are located in San Francisco, California. Significantly, on February 13, 2024, Invitae Corporation, alongside its associated entities, formally initiated Chapter 11 bankruptcy reorganization proceedings in the U.S. Bankruptcy Court for the District of New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Aug 9, 2022 | -$0.68+10.88% vs estimate | $136.62M-0.16% vs estimate |
|---|
| Q4 2021 | Mar 30, 2022 | -$0.80-4.32% vs estimate | $123.69M-9.61% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.93-$0.19 (-8.77%)
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.00-$0.05 (-99.6%)
StatSure Diagnostic Systems, Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Cell Kinetics Ltd.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
PotNetwork Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Predictive Technology Group, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Nexeon MedSystems Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Health-Chem Corporation: Healthcare · Medical - Diagnostics & Research.
$0.00$0.00 (0.0%)
Clarus Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
